Supernus Pharmaceuticals, Inc.
SUPN
Jodie situation report
Supernus Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.
- Revenue increased 38.6% versus the comparable filing period.
- ONAPGO demand was described as stronger than expected, while supplier constraints limited Supernus' ability to fully meet it.
- The accretion of a Sage contingent value right (CVR) to the full milestone payment occurred with approval of ZURZUVAE for MDD in Japan.
Invalidation: The isolated read changes if SUPN's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind SUPN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BIIBBiogen Inc.partnerMay 5, 2026 ▾
“The Company and our collaboration partner, Biogen, are jointly commercializing ZURZUVAE in the U.S.”
SGIOFFiling-linked namecustomerMar 2, 2026 ▾
“The Company concluded that Shionogi meets the definition of a customer because the Company is delivering intellectual property and know-how rights for the zuranolone program in support of 120 Table of Contents Supernus Pharmaceuticals, Inc.”
Depended on by
BIIBBiogen Inc.partnerApr 29, 2026 ▾
“COLLABORATION PROFIT SHARING/(LOSS REIMBURSEMENT) Collaboration profit sharing/(loss reimbursement) includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars 2013 commercial agreement with Samsung Bioepis and collaboration profit…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 13 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
SUPN is currently a Leader in the organic co-movement group CNS Pharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for SUPN; it is not active in the latest market snapshot.